Catherine Forconi to Burkitt Lymphoma
This is a "connection" page, showing publications Catherine Forconi has written about Burkitt Lymphoma.
Connection Strength
1.333
-
Forconi CS, Cosgrove CP, Saikumar-Lakshmi P, Nixon CE, Foley J, Ong'echa JM, Otieno JA, Alter G, M?nz C, Moormann AM. Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas. Blood Adv. 2018 05 22; 2(10):1101-1114.
Score: 0.578
-
Muriuki BM, Forconi CS, Kirwa EK, Maina TK, Ariera BO, Bailey JA, Ghansah A, Moormann AM, Ong'echa JM. Evaluation of KIR3DL1/KIR3DS1 allelic polymorphisms in Kenyan children with endemic Burkitt lymphoma. PLoS One. 2023; 18(8):e0275046.
Score: 0.208
-
Saikumar Lakshmi P, Oduor CI, Forconi CS, M'Bana V, Bly C, Gerstein RM, Otieno JA, Ong'echa JM, M?nz C, Luftig MA, Brehm MA, Bailey JA, Moormann AM. Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. Life Sci Alliance. 2023 05; 6(5).
Score: 0.201
-
Muriuki BM, Forconi CS, Oluoch PO, Bailey JA, Ghansah A, Moormann AM, Ong'echa JM. Association of killer cell immunoglobulin-like receptors with endemic Burkitt lymphoma in Kenyan children. Sci Rep. 2021 05 31; 11(1):11343.
Score: 0.178
-
Oluoch PO, Oduor CI, Forconi CS, Ong'echa JM, M?nz C, Dittmer DP, Bailey JA, Moormann AM. Kaposi Sarcoma-Associated Herpesvirus Infection and Endemic Burkitt Lymphoma. J Infect Dis. 2020 06 16; 222(1):111-120.
Score: 0.167